ESR1 mutation as an emerging clinical biomarker in metastatic …
Aug 15, 2021 — Well-established findings are: (1) ESR1 mutations are acquired during AI treatment in the metastatic setting; (2) ESR1 mutations predict resistance to AI monotherapy; …
Testing for ESR1 Mutations to Guide Therapy for Hormone …
May 17, 2023 — Updated Recommendations. To aid in treatment selection, the Expert Panel recommends routine testing for emergence of ESR1 mutations at recurrence or progression …
ESR1 Gene - GeneCards | ESR1 Protein | ESR1 Antibody
Oct 1, 2024 — ESR1 (Estrogen Receptor 1) is a Protein Coding gene. Diseases associated with ESR1 include Estrogen Resistance and Breast Cancer. Among its related pathways are …
ASCO Guidelines - ASCO Publications
May 17, 2023 — Dr. Angie DeMichele and Dr. Lynn Henry present the latest rapid recommendation impacting two ASCO guidelines. This update focuses on testing for ESR1 mutations in …
Sed rate (erythrocyte sedimentation rate) - Mayo Clinic
Sed rate, or erythrocyte sedimentation rate (ESR), is a blood test that can show inflammatory activity in the body. Many health problems can cause a sed rate test result to be outside the …
ESR1 mutations and therapeutic resistance in metastatic breast …
These mutations are particularly detrimental in metastatic breast cancer (MBC) as they are present in as high as 36% of the patients. This review summarises the pre-clinical …
ESR1 activating mutations: From structure to clinical application
Jan 1, 2023 — To date, over 50 point mutations in ESR1 have been detected in clinical samples of breast cancer. However, most mutations that are pathogenic and putatively result in ET …
ESR1 mutations—a mechanism for acquired endocrine resistance …
Jun 30, 2015 — Massively parallel next-generation sequencing techniques enable the quantification of the proportion of cells harbouring a given mutation in cancer, but their inherent error rate of …
ESR1 mutations in breast cancer - PubMed
Nov 1, 2019 — The acquisition of ligand-independent ESR1 mutations during aromatase inhibitor therapy in metastatic estrogen receptor (ER)-positive breast cancer is a common mechanism …
ESR1 mutations—a mechanism for acquired endocrine resistance ... - PubMed
In the past 2 years, several studies unveiled gain-of-function mutations in ESR1, the gene encoding the ER, in approximately 20% of patients with metastatic ER-positive disease who …